NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities today initiated coverage of synthetic biology firm Intrexon with a Buy rating and a price target on the company's shares of $30.

Germantown, Md.-based Intrexon went public in August, raising $184 million in gross proceeds. Mizuho was co-manager on the IPO with Griffin Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.